CROSSJECT CROSSJECT - AFPric Study:
PATIENTS APPROVE NEEDLE-FREE INJECTION
- 81% of patients with polyarthritis see improvements with a needle-free injection device
- 86% are ready to use this new device, 75% of which use needles or injection pens
- 94% say it is important that the discomfort related to hands was taken into account
Chenôve (France), 10 May 2016, 5:45 pm - Crossject (ISIN: FR0011716265 ; Mnemo: ALCJ), a laboratory specialized in auto-injection drugs dedicated to emergency situations, and AFPric, the largest French association of patients with polyarthritis and chronic inflammatory rheumatisms, pursued their collaboration and released today the main findings of a study conducted with members of AFPric on their treatment and their interest in needle-free injection.
The study reveals that patients with rheumatoid polyarthritis are largely prepared to use needle-free injection as part of their treatment. 85.9% of respondents are ready to use a needle-free injection device, three quarters of which are currently taking their treatment with injection.
In addition, 71% of respondents think that this device could reduce constraints related to their treatments and 77% say it could help to take it better.
It should also be noted that 88% of respondents want to be informed about the progress of the device.
The study finally confirms practitioners' feedback: many patients combine oral and injection forms as part of their long-term treatments. 71.8% of patients use subcutaneous injection and 55.4% resort to an oral treatment.
The respondents have been suffering from polyarthritis for an average of 15.4 years and are mostly women (which is in line with epidemiology), aged 60.3.
Patrick Alexandre, President and founder of CROSSJECT, said: "The study conducted by AFPric suggests that Zeneo® will be favorably welcomed by patients, who approve easy needle-free injection. Understanding the real needs of patients is at the heart of our strategy. We are very pleased to observe that the patients surveyed are convinced that our technology provides them with a real comfort and improves their everyday lives. Our collaboration with AFPric confirmed our intuition: patients with polyarthritis have a real interest in our technology Zeneo® that answers their needs for ergonomics and convenience."
Isabelle Reynaud-Verdière, President of the AFPric, added: "Not only does our association aim to support patients with rheumatoid polyarthritis but its objective is also to make research progress. Collaborating with companies such as Crossject, which offers patients with rheumatoid polyarthritis greater autonomy through its technology, takes fully part in the missions of our association. Nearly 1,000 members answered the questionnaire and our study reveals that the technology Zeneo® represents a real development for chronic patients awaiting innovative solutions to better tolerate their treatments every day."
As a reminder, the collaboration between AFPric and Crossject enabled to improve the needle-free auto-injection device Zeneo®. The packaging was reviewed to facilitate its opening and the user guide was simplified. The ergonomics and the design of the cork were also improved, especially to ensure a better pick up for the user. In the same spirit, the cover was equipped with a "grip" to avoid a slippery effect.
Tests were conducted and confirmed the adaptation of the device to patients' needs.
CROSSJECT should file for marketing authorization and proceed to the launch of for Zeneo® Methotrexate during 2017's second semester.
Zeneo® Methotrexate is the first treatment developed by CROSSJECT and the only one not dedicated to emergency situations. Methotrexate is used as a chronical treatment to rheumatoid arthritis, representing a market of 2.5 billion Euros1 (in Europe and in the USA). CROSSJECT aims at producing 8 million doses per year, which represent 15% of the market in volume, for a public price comprised between 20 Euros in Europe and Asia and 120 Dollars in the US.
The study was conducted with 973 patients and members of AFPric the in May and June 2015.
Press contacts:
| Crossject Patrick Alexandre / Timothée Muller info@crossject.com | Citigate Dewe Rogerson Laurence Bault +33 (0)1 53 32 84 78 laurence.bault@citigate.fr | AFPric Cyrielle Beller +33 (0)1 40 03 02 00 afpcom@nerim.net |
Investor relations
Benjamin Lehari
+33 (0)1 56 88 11 25
blehari@actifin.fr
About CROSSJECT · www.crossject.com
CROSSJECT is using its world-leading needle-free injection system, Zeneo® to develop an attractive pipeline of high-value supergenerics or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.
CROSSJECT's needle-free, pre-filled, single-use Zeneo® injection systems are unique in that they can be tailored to deliver drugs intradermally, subcutaneously and intramuscularly. This means that Zeneo® can allow a wide range of drugs and vaccines for a broad range of indications to be developed and approved in a very short period.
CROSSJECT's business model is similar to that of a pharmaceutical laboratory. It is based on developing a portfolio of proprietary drugs, of an integrated supply chain and the signing of distribution agreements for its products.
CROSSJECT currently develops 7 drugs: anaphylactic shock (adrenaline), rheumatoid arthritis (methotrexate), acute migraine (sumatriptan), Parkinson's disease (apomorphine), the morphine overdose (naloxone), disorders of the anxiety and pesticide poisoning (midazolam) and a seventh medicine for an emergency situation that could benefit from an "orphan status".
CROSSJECT is listed on Alternext Paris (Mnemo: ALCJ, ISIN: FR0011716265)
About AFPric:
Largest French association of patients with rheumatoid arthritis, AFPric is an association created in 1988 and recognized of public utility. It is represented throughout France, with 70 local offices spread across the country in France and overseas territories. One of these missions is to improve the lives of patients.
Disclaimer
Some of the statements contained in this press release constitute forward-looking statements. These statements constitute either expectations or goals and shall not be considered as future results or any other performance indicators. These statements involve risks and uncertainties, out of control of the company in certain cases, especially during a R&D process. A detailed description of these risks and uncertainties is to be found in the Document de Base of the company, available on its website (www.crossject.com)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CROSSJECT via Globenewswire
